SCHEMBL232237

SCHEMBL232237

CN(c1ccc(Cl)cc1)c1ccc(C(=O)c2cc(C(=O)O)cc(N(C)c3ccc(Cl)cc3)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 4/20 0.56
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
LTC4S Q16873 7/20 0.46
RXRA P19793 1/20 0.45
NR4A2 P43354 1/20 0.45
LMNA P02545 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
HPGD P15428 3/20 0.44
MAPT P10636 2/20 0.44
ALDH1A1 P00352 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
MAPK1 P28482 1/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230136 0.96 SRD5A2 (0.51) SRD5A2ALOX15TSHRLTC4SRXRA
SCHEMBL2743187 0.90 SRD5A2 (0.47) SRD5A2ALOX15TSHRLTC4SRXRA
SCHEMBL2743197 0.87 LTC4S (0.43) SRD5A2LTC4SRXRANR4A2LMNA
SCHEMBL2743184 0.86 SRD5A2 (0.47) SRD5A2ALOX15TSHRLTC4SLMNA
SCHEMBL2743161 0.86 LMNA (0.48) SRD5A2LTC4SLMNAL3MBTL1HPGD
SCHEMBL2743193 0.85 LMNA (0.44) SRD5A2LTC4SRXRANR4A2LMNA
SCHEMBL2743209 0.84 LMNA (0.46) SRD5A2ALOX15TSHRLTC4SLMNA
SCHEMBL233238 0.84 SRD5A2 (0.51) SRD5A2LTC4SLMNAL3MBTL1HPGD
SCHEMBL2743185 0.84 MAPK13 (0.47) SRD5A2ALOX15LTC4SLMNAL3MBTL1
SCHEMBL232400 0.84 HPGD (0.46) SRD5A2LTC4SLMNAL3MBTL1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2406220-A1 BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS Biolipox AB (SE) 2012-01-18 EP disclosed
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed
WO-2010103279-A1 BIS AROMATIC COMPOUNDS FOR USE AS LCT4 SYNTHASE INHIBITORS BIOLIPOX AB (SE) 2010-09-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R SRD5A2 564/4885ALOX15 8/4885TSHR 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.